Yes, marijuana can be addictive. Approximately 9% of people who use cannabis will develop cannabis use disorder (CUD), rising to 17% among those who begin in adolescence and 25 to 50% among daily users according to NIDA estimates. Cannabis produces its psychoactive effects through delta-9-tetrahydrocannabinol (THC), which activates CB1 cannabinoid receptors in the brain’s reward, memory, and executive function circuits. Chronic THC exposure causes receptor downregulation, tolerance, and a withdrawal syndrome that, while not life-threatening, drives continued use. The increasing potency of modern cannabis products, with THC concentrations rising from 4% in the 1990s to over 20% in flower and 60 to 90% in concentrates, has increased both the speed and severity of dependence development.
Clinically reviewed by Dr. Ponlawat Pitsuwan, Physician, Phuket Island Rehab
“Cannabis use disorder is one of the most underdiagnosed substance use conditions we encounter,” says Dr. Ponlawat Pitsuwan. “At Phuket Island Rehab, patients presenting with cannabis dependence often arrive sceptical that their use qualifies as addiction. They have been told, and often believe, that cannabis is not addictive. When we explain the neuroscience of CB1 receptor downregulation and they recognise their own experience in the withdrawal symptoms and loss of control we describe, there is often a moment of recognition that reframes their entire relationship with the substance.”
How THC Acts on the Brain
Delta-9-tetrahydrocannabinol (THC) is the primary psychoactive compound in cannabis. It acts as a partial agonist at CB1 cannabinoid receptors, which are among the most abundant G-protein coupled receptors in the human brain. CB1 receptors are densely concentrated in the hippocampus (memory), prefrontal cortex (executive function), basal ganglia (motor control and habit formation), amygdala (emotion), and cerebellum (coordination). When THC binds CB1 receptors, it modulates neurotransmitter release, producing the characteristic effects of cannabis: euphoria, relaxation, altered time perception, impaired short-term memory, and increased appetite.
THC also activates the mesolimbic dopamine pathway, increasing dopamine release in the nucleus accumbens. This dopamine release, while more modest than that produced by cocaine or amphetamines, is the mechanism through which cannabis produces rewarding effects and reinforces use. The rewarding signal is sufficient to drive habit formation and, in vulnerable individuals, compulsive use. The endocannabinoid system, which THC mimics, normally uses endogenous ligands anandamide and 2-arachidonoylglycerol (2-AG) to regulate mood, appetite, pain, and stress response. Chronic THC exposure disrupts this regulatory system by downregulating CB1 receptors and reducing endocannabinoid tone.
The Rising Potency Problem
The cannabis available today is substantially different from what was used in previous decades. Average THC content in cannabis flower has increased from approximately 4% in the early 1990s to over 20% in current products. Concentrated forms such as wax, shatter, budder, and distillate contain 60 to 90% THC. This potency escalation means that modern cannabis users are exposing their CB1 receptors to far higher THC concentrations than users in previous generations, which accelerates tolerance development and increases the risk and severity of dependence.
The analogy to alcohol is instructive: there is a significant clinical difference between drinking beer at 5% alcohol and drinking spirits at 40%, even though both deliver the same molecule. Similarly, there is a meaningful difference between smoking cannabis at 4% THC and dabbing concentrates at 80% THC. The dose-response relationship means that higher potency increases the speed of neuroadaptation, the severity of tolerance, the intensity of withdrawal, and the likelihood of developing cannabis use disorder.
Cannabis Use Disorder: DSM-5 Criteria
| DSM-5 Criterion | What This Looks Like in Practice |
|---|---|
| Using more or for longer than intended | Planning to smoke one bowl and finishing the entire supply |
| Persistent desire or unsuccessful efforts to cut down | Repeatedly deciding to take a break and being unable to follow through |
| Spending significant time obtaining, using, or recovering | Organising daily schedule around use; spending mornings foggy and unproductive |
| Craving | Thinking about cannabis frequently when not using; feeling pulled to use |
| Failure to fulfil major obligations | Declining work performance, missed deadlines, academic problems |
| Continued use despite social or interpersonal problems | Partner conflict over use; withdrawal from non-using friends |
| Important activities given up or reduced | Hobbies, exercise, socialising replaced by use |
| Use in physically hazardous situations | Driving while impaired; operating equipment |
| Continued use despite physical or psychological problems | Using despite worsening anxiety, memory problems, or respiratory symptoms |
| Tolerance | Needing more cannabis or stronger products for the same effect |
| Withdrawal | Irritability, insomnia, decreased appetite, anxiety, restlessness when stopping |
Two or more criteria within a twelve-month period constitute a diagnosis of cannabis use disorder. Mild (2 to 3 criteria), moderate (4 to 5), and severe (6 or more) specifiers indicate the degree of clinical concern.
Cannabis Withdrawal Syndrome
Cannabis withdrawal was formally recognised in the DSM-5 and is experienced by the majority of daily or near-daily users who stop abruptly. Symptoms typically begin within 24 to 72 hours of cessation, peak at approximately one week, and gradually resolve over 2 to 4 weeks. The core symptoms include irritability and anger, anxiety or nervousness, sleep disturbance (insomnia and vivid dreams), decreased appetite and weight loss, restlessness, depressed mood, and at least one physical symptom such as abdominal pain, sweating, fever, chills, or headache.
Cannabis withdrawal is not medically dangerous in the way that alcohol or benzodiazepine withdrawal can be, but it is sufficiently uncomfortable to drive relapse in many users. The insomnia component is particularly persistent and distressing, often lasting 2 to 6 weeks, because the endocannabinoid system plays a significant role in sleep regulation. The vivid, often disturbing dreams that accompany cannabis withdrawal are thought to result from the rebound of REM sleep, which THC suppresses during active use.
Clinical insight: Many patients at Phuket Island Rehab are surprised by the intensity of cannabis withdrawal because they expected none. The sleep disruption and irritability can be significant enough to affect relationships and work performance, which reinforces the pattern of using cannabis “just to function normally,” the defining sign that dependence has developed.
Adolescent Vulnerability
The adolescent brain is particularly vulnerable to cannabis-related harm because it is still undergoing critical neurodevelopmental processes, particularly in the prefrontal cortex, which continues developing until approximately age 25. Regular cannabis use during adolescence is associated with reduced IQ (with persistent effects in some studies even after cessation), impaired working memory and processing speed, increased risk of psychotic disorders (particularly in individuals with genetic vulnerability, such as carriers of the Val/Val variant of the COMT gene), and a significantly higher rate of cannabis use disorder development (17% versus 9% for adult-onset users).
The endocannabinoid system plays a crucial role in adolescent brain development, guiding synaptic pruning and myelination in the prefrontal cortex. Chronic THC exposure during this developmental window disrupts these processes, potentially causing neurodevelopmental effects that persist into adulthood. This is the strongest evidence-based argument for delaying cannabis use, and it applies regardless of legal status or personal beliefs about cannabis policy.
When Substance Use Has Become More Than Occasional
If you are using cannabis daily or near-daily, if you have tried to cut down or stop and found it difficult, if your use has increased over time, if you feel irritable or unable to sleep without cannabis, or if your use is interfering with your relationships, work, or motivation, these patterns indicate cannabis use disorder. The cultural normalisation of cannabis use does not change the pharmacological reality of CB1 receptor downregulation and the behavioural consequences that follow.
Cannabis use disorder is treatable. Cognitive behavioural therapy, motivational enhancement therapy, and contingency management have the strongest evidence base. For individuals with severe dependence or co-occurring conditions, residential treatment at Phuket Island Rehab provides the structured environment, clinical support, and distance from use-enabling environments that support sustained recovery.
Summary
Cannabis is addictive in a clinically meaningful proportion of users. THC acts on CB1 cannabinoid receptors in the brain’s reward, memory, and executive function systems, producing neuroadaptation that leads to tolerance, withdrawal, and compulsive use in vulnerable individuals. The increasing potency of modern cannabis products has accelerated dependence development, and adolescent users face particular neurodevelopmental risks. Cannabis withdrawal, while not medically dangerous, is real and sufficiently uncomfortable to drive continued use. Cannabis use disorder is a recognised clinical condition with effective evidence-based treatments.
“The statement ‘cannabis is not addictive’ has done real harm to people who are struggling with their use,” says Dr. Ponlawat Pitsuwan. “It tells them that their experience of loss of control, withdrawal, and functional impairment is not real, or worse, that it reflects personal weakness rather than a neurobiological process. At Phuket Island Rehab, we validate the patient’s experience by explaining the science: CB1 receptor downregulation, endocannabinoid system disruption, and tolerance are documented phenomena. Cannabis use disorder is a real condition, and recovery is achievable.”
Frequently Asked Questions
What percentage of cannabis users become addicted?
Approximately 9% of all cannabis users develop cannabis use disorder. The rate rises to approximately 17% among those who begin using in adolescence and 25 to 50% among daily users. These figures come from large epidemiological studies including the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC) and have been consistent across multiple populations and time periods.
Is cannabis withdrawal real?
Yes. Cannabis withdrawal syndrome is formally recognised in the DSM-5 and ICD-11. It is experienced by the majority of daily users who stop abruptly and includes irritability, anxiety, insomnia, vivid dreams, decreased appetite, restlessness, and depressed mood. Symptoms begin within 24 to 72 hours, peak at about one week, and generally resolve within 2 to 4 weeks, though sleep disturbance may persist for up to 6 weeks.
Does higher THC content make cannabis more addictive?
Higher THC concentrations produce more intense CB1 receptor activation, which accelerates neuroadaptation (tolerance and dependence). Research has shown that use of high-potency cannabis is associated with faster progression to daily use, more severe dependence, and greater difficulty quitting. The relationship is dose-dependent: more THC per use session means faster and deeper receptor downregulation, which means faster development of tolerance and physical dependence.
Can cannabis cause psychosis?
Cannabis use, particularly heavy use of high-THC products during adolescence, is associated with an increased risk of psychotic disorders including schizophrenia. The risk is dose-dependent and is elevated in individuals with genetic vulnerability, particularly carriers of certain COMT gene variants. A meta-analysis published in The Lancet Psychiatry found that daily use of high-potency cannabis was associated with approximately five times greater odds of developing a psychotic disorder compared to non-users. Cannabis does not cause psychosis in everyone, but it is a significant risk factor in vulnerable individuals.
Is CBD addictive?
Cannabidiol (CBD) does not appear to be addictive. The WHO Expert Committee on Drug Dependence concluded in 2017 that CBD exhibits no effects indicative of abuse or dependence potential. CBD does not bind directly to CB1 receptors and does not produce the euphoria, reinforcement, or neuroadaptation that characterise THC. However, many products marketed as “CBD” contain variable amounts of THC, and some contain enough THC to produce psychoactive effects and, with chronic use, dependence. Product quality and labelling accuracy remain significant concerns in the largely unregulated CBD market.
How long does it take to recover from cannabis dependence?
CB1 receptor density, measured by PET imaging, begins recovering within 2 days of cessation and shows substantial normalisation by 4 weeks. However, full functional recovery, including normalisation of sleep, appetite, mood, and cognitive function, typically takes 1 to 3 months for moderate users and up to 6 months or longer for heavy, long-term users. Cognitive functions such as memory and processing speed may take the longest to fully normalise, particularly in individuals who began using heavily during adolescence.
Sources
National Institute on Drug Abuse (NIDA). “Marijuana DrugFacts.” National Institutes of Health. drugabuse.gov
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). Cannabis Use Disorder criteria.
Di Forti M, et al. “The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe.” Lancet Psychiatry. 2019;6(5):427-436.
Cannabis · THC (delta-9-tetrahydrocannabinol) · CBD (cannabidiol) · CB1 receptor · Endocannabinoid system · Anandamide · 2-AG · Dopamine · Nucleus accumbens · Cannabis use disorder · DSM-5 · Cannabis withdrawal syndrome · COMT gene · Prefrontal cortex · Synaptic pruning · Phuket Island Rehab